What does JNCE mean in NASDAQ SYMBOLS
JNCE is the ticker symbol for Jounce Therapeutics, Inc., a clinical-stage immunotherapy biotechnology company, which is headquartered in Cambridge, Massachusetts. The company utilizes proprietary product candidates to treat various forms of cancer by promoting immune system activity against tumors. It specializes in manufacturing monoclonal antibodies (mAbs) and cytokines that target various immune cell receptors, as well as specific tumor antigens.The company was founded in 2013 and has since developed a strong pipeline of therapies that could potentially transform the treatment landscape for many different types of cancer.
JNCE meaning in NASDAQ Symbols in Business
JNCE mostly used in an acronym NASDAQ Symbols in Category Business that means Jounce Therapeutics Inc
Shorthand: JNCE,
Full Form: Jounce Therapeutics Inc
For more information of "Jounce Therapeutics Inc", see the section below.
Essential Questions and Answers on Jounce Therapeutics Inc in "BUSINESS»NASDAQ"
What is Jounce Therapeutics Inc.?
Jounce Therapeutics Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients.
What is Immunotherapy?
Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight disease. It works by using substances either made by the body or in a laboratory to boost, direct, or restore the body’s natural defenses against disease.
What types of cancer does Jounce Therapeutics target?
Jounce focuses on solid tumors, including triple-negative breast cancer, non-small cell lung cancer, metastatic melanoma, pancreatic cancer and head and neck cancers.
How does Jounce’s therapy work?
The therapy works by targeting “immune checkpoints” which are proteins on specific cells that can act as brakes on the immune system and prevent it from attacking tumor cells effectively. By using antibodies or small molecules to block these checkpoints, T cell activation can be boosted and activate an anti-tumor response. This can lead to tumor regression or control tumor growth.
What products does Jounce develop?
Jounce develops monoclonal antibodies and small molecule drugs for use in combination with other targeted therapies or immunotherapies for treating tumors. Currently their most advanced product candidate is vopratelimab, an anti-PDL1 IgG4 monoclonal antibody being developed in combination with chemotherapy for the treatment of certain types of solid tumors.
Where do I find updates on products in development?
Investors may find up-to-date information about Jounce’s products in development on their website at https://jouncetx.com/investors/. Additionally, investors may also follow news regarding clinical studies related to these products through ClinicalTrials.gov (https://clinicaltrials.gov/)
Final Words:
In conclusion, JNCE stands for Jounce Therapeutics, Inc., a clinical-stage immunotherapy biotechnology company committed to developing mAbs and cytokines that can activate an individual’s own immune system to combat malignant tumors more effectively than traditional chemotherapy or radiation therapies alone. Its revolutionary approach promises great potential in treating various types of cancer with far fewer side effects than traditional treatments might provide. By using its Translational Science Platform, genomics sequencing, and predictive analytics technologies, it is striving towards revolutionizing how we can diagnose diseases like cancer at an earlier stage while providing tailored treatment solutions that are specifically designed for each individual patient based on their unique molecular profile.